Aerie shares rocket up as glaucoma combo drug scores positive data
Shares of Aerie Pharmaceuticals $AERI skyrocketed on promising data for a combination glaucoma drug that bested its own late-stage drug Rhopressa by adding a well known and widely prescribed generic treatment that significantly improves its effect.
Aerie has filed for an FDA OK on Rhopressa, but investors were quick to turn their attention this afternoon to Roclatan, which adds the generic latanoprost to the mix. The combo drug hit the primary endpoint, according to Aerie, lowering intraocular pressure significantly better than either latanoprost or Rhopressa alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
